GLPwatch

Exendin-4 reduces food intake via the PI3K/AKT signaling pathway in the hypothalamus.

Sci Rep · 2017

Last updated 2026-05-28

In a study on rats, the GLP-1 drug Exendin-4 (EX-4) reduced food intake and body weight. Blocking a specific brain pathway (PI3K/AKT) with a chemical called wortmannin prevented these effects, suggesting EX-4 works through this pathway. EX-4 also increased activity in insulin-related signals in the brain.

AI summary of the abstract below.

JournalSci Rep, 2017
Citations24
Relative citation ratio0.97
NIH percentile49
Molecules
Conditions studied Obesity

Abstract

Exendin-4 (EX-4), a glucagon-like peptide-1 (GLP-1) receptor agonist, has been shown to reduce food intake and to increase proopiomelanocortin (POMC) gene expression in the hypothalamus. In this study, we examined the potential neural mechanisms by which these effects occur. Male Sprague Dawley rats were implanted with a cannula in the third ventricle of the brain through which an inhibitor of phosphatidylinositol-3 kinase (PI3K) (wortmannin) was administered, and EX-4 or vehicle was administered via intraperitoneal (IP) injection. The activity of PI3K/protein kinase B (AKT) and insulin receptor substrate-1 (IRS-1) in the hypothalamic arcuate was determined. We found that EX-4 treatment significantly decreased food intake and body weight. However, there were almost no changes in food intake and body weight when wortmannin injection (into the third ventricle) occurred prior to EX-4 IP injection. EX-4 not only increased the activity of PI3K/AKT, but it also increased IRS-1 activity. These results show that EX-4 likely suppresses food intake due to its ability to enhance insulin signaling.

Verbatim abstract via PubMed 28761132 ↗